SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 4

Myopic Choroidal Neovascularization

Miyopik Koroidal Neovaskülarizasyon

ZİYA AYHAN
A. Osman SAATCİ
Pages
280–284
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article aims to review the epidemiology, pathophysiology, clinical features and treatment of mCNV

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration.
📊
Key Findings & Data:Previous therapies employed in 2000’s such as photodynamic therapy have shown limited visual improvement.
💡
Conclusion & Impact:This article aims to review the epidemiology, pathophysiology, clinical features and treatment of mCNV
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration. It is a complication of pathologic myopia that occurs mostly in young adult ages and affects the quality of life negatively. Previous therapies employed in 2000’s such as photodynamic therapy have shown limited visual improvement. Anti-vascular endothelial growth factor therapy (anti-VEGF) has been shown to be effective in the treatment of mCNV in several multicentric studies and has become the first-line treatment of choice. This article aims to review the epidemiology, pathophysiology, clinical features and treatment of mCNV

Özet

Miyopik koroidal neovaskülarizasyon (mKNV), yaşa bağlı maküla dejenerasyonundan sonra koroidal neovaskülarizasyonun en sık görülen ikinci nedenidir. Patolojik miyopiye eşlik eden bir komplikasyon olup daha çok genç erişkin yaşlarda görülmekte ve hayat kalitesini olumsuz yönde etkilemektedir. Tedavide, 2000'li yıllarda kullanılan fotodinamik tedavi ile sınırlı görsel kazanç sağlandığı gösterilmiştir. Ancak, vasküler endotelyal büyüme faktörü antagonistleri ile mKNV tedavisinde çok merkezli çalışmalarda çok olumlu sonuçlar elde edildiği için tedavide altın standart haline gelmişlerdir. Bu derlemede mKNV'nin epidemiyolojisi, patofizyolojisi, klinik özellikleri ve tedavisinin gözden geçirilmesi amaçlanmıştır

🔖

Cite This Article

AYHAN, Z., SAATCİ, A. O. (2017). Myopic Choroidal Neovascularization. Güncel Retina Dergisi, Cilt: 1 - Sayı: 4, 280–284. https://ajindex.com/articles/196205

References (15)

  1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–48
  2. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9–25
  3. Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology. 2010;117:1763–8
  4. Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: The Tajimi Study. Ophthalmology 2006;113:1354–62
  5. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology 2004;111:62–9
  6. Teo K, Gemmy Cheung C. Choroidal neovascularization secondary to pathological myopia. World J Ophthalmol. 2014;4:35–46
  7. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog 1130 K. Y. C. Teo et al. Retina Eye Res. 2012;31:495–525
  8. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595–611
  9. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87:570–3
  10. Ikuno Y, Sayanagi K, Soga K, Sawa M, Gomi F, Tsujikawa M, et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 2008;28:1124–31
  11. Curtin BJ. Physiologic vs pathologic myopia: Genetics vs environment. Ophthalmology 1979;86:681–91
  12. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci. 1999;40:3287–91
  13. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol. 2010;94:611–5
  14. Young TL. Dissecting the genetics of human high myopia: a molecular biologic approach. Trans Am Ophthalmol Soc. 2004;102:423–45
  15. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923–6. 16.